Onverwacht uterien bloedverlies bij methylfenidaat

Abstract

Unexpected methylphenidate-induced uterine bleeding In most countries, methylphenidate appears to be the main pharmacological treatment for attention deficit hyperactivity disorder (ADHD). The global prevalence of ADHD is estimated to be approximately 2.5% in adults and 5-7% in children. This case report examines the link between the initiation of extended-release methylphenidate and the occurrence of unexpected uterine bleeding in a patient, aiming to determine if there is any scientific basis for considering this symptom as a side effect of methylphenidate. Although there are some suspicions in the literature, the evidence is still too limited to explain a causal relationship between methylphenidate and unexpected uterine bleeding. In recent years, scientific studies have shown a growing awareness of ADHD in the female population, while women and girls were previously diagnosed with ADHD much less frequently and much later. However, this phenomenon of underrepresentation of women still occurs in the available scientific literature, especially in somewhat older studies. In future research, an important challenge lies in further monitoring any potential effects of methylphenidate on the female reproductive system, adequately reporting contraceptive use in study populations, as well as detailing all adverse events and reasons for study dropouts.